Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib PK in renal impairment
NCT06190678Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration, Time to Maximum Observed Plasma Concentration and 6 more. Started Feb 2021; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06190678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190678.